HERON Neutron Medical and PELL Bio-Med Sign MOU for Strategic Alliance

  

Source: Economic Daily News (Taiwan)

 

Focusing on Combined “AB-BNCT and Immunotherapy” Research and Translation

Defining the Next Generation of Precision Cancer Treatment Technologies

 

HERON Neutron Medical Corp. (hereinafter referred to as "HERON") and PELL Bio-Med Technology Co. Ltd. (hereinafter referred to as "PELL Bio-Med") announced today that the two parties have signed a "Memorandum of Understanding (MOU) for Strategic Alliance." The partnership aims to develop precision treatment techniques combining Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) with Immunotherapy, jointly advancing preclinical research, translational validation, and subsequent clinical application development.

 

Synergy of Two Cutting-Edge Technologies

 HERON specializes in the development of AB-BNCT medical equipment and therapeutic drugs, while PELL Bio-Med focuses on the research and development of CAR-T cell therapy. This collaboration integrates next-generation radiotherapy (AB-BNCT) with immunotherapy (CAR-T) to create a world-first treatment platform targeting both non-solid and solid tumors. The goal is to expand the scope of advanced cancer treatment and provide patients with more comprehensive medical services.

 

Strategic Goals and Key Areas of Cooperation

 Under the framework of the MOU, the collaboration aims to synergize the core strengths of both partners:

• HERON Neutron Medical’s Expertise: Leveraging its advanced AB-BNCT treatment platforms, specialized clinical applications for solid tumors, and sophisticated treatment planning technologies.

• PELL Bio-Med’s Capabilities: Utilizing its robust research and development in immunotherapy and its leadership in translational medical development.

Moving forward, the two parties will initiate theoretical studies and evaluation of potential indications for combination therapy. These joint assessments are designed to provide the scientific foundation and feasibility validation required for this pioneering combined treatment strategy. 

Leadership Perspectives

 "The combined use of cellular immunotherapy and AB-BNCT holds immense clinical value. PELL Bio-Med owns the first locally developed and manufactured CAR-T product in Taiwan. The upcoming human clinical trials for our next-generation CAR-T, as well as the validation of combination therapies with AB-BNCT, require rigorous teamwork and clinical coordination. By collaborating with HERON’s established AB-BNCT platform in hospitals, we aim to build the world’s first treatment platform capable of addressing most cancers—including both liquid and solid tumors—while accelerating the exploration of combined therapy feasibility." — Prof. Steve CL Lin, Founder of PELL Bio-Med Technology Co. Ltd.

  

"AB-BNCT offers distinct advantages in the precision treatment of solid tumors. The immunogenic cell death and changes in the tumor microenvironment triggered by tumor ablation create a strategic opening for combined immunotherapy. Establishing this framework with PELL Bio-Med will allow us to systematically advance feasibility studies and clinical evaluations for this next-generation therapy." — Leo Shen, President of HERON Neutron Medical 

---